Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAIVE PATIENTS WITH RECURRENT GBM
PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAIVE PATIENTS WITH RECURRENT GBM Reardon, D., Kaley, T., Dietrich, J., Lim, M., Dunn, G., Gan, H., Cloughesy, T., Clarke, J., Park, A., Macri, M., Ryan, A., Ricciardi, T., Reddy, V., Venhaus, R. OXFORD UNIV PRESS INC. 2016: 18View details for Web of Science ID 000398604101005